ARTICLE | Top Story

Genzyme, Voyager in CNS gene therapy tie-up

February 12, 2015 2:23 AM UTC

Voyager Therapeutics Inc. (Cambridge, Mass.) and the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) partnered to develop and commercialize Voyager's gene therapies for CNS diseases.

The deal gives Genzyme options to license ex-U.S. rights to three therapies after a human proof-of-concept trial is complete for each: VY-AADC01 to treat Parkinson's disease (PD), VY-FXN01 to treat Friedreich's ataxia (FRDA) and VY-HTT01 for Huntington's disease (HD). Genzyme also has an option to co-commercialize VY-HTT01 in the U.S. ...